Levitate Bio

Levitate Bio is a private, platform-focused biotech company that emerged from the Nobel-prize winning scientific ecosystem of David Baker's lab. It offers a cloud-based software platform that democratizes access to advanced computational protein design tools, primarily from the Rosetta software suite, for biopharma and academic researchers. The company operates a B2B business model, generating revenue by providing its platform and services to over 140 biopharma clients, including 13 of the top 20 global pharmaceutical companies. Its mission is to accelerate drug discovery and development by removing technical barriers in protein engineering.

A cloud-based software platform that curates, automates, and delivers advanced protein modeling and design tools from the Rosetta Commons software suite, enhanced by AI. It provides workflows for protein stabilization, solubilization, affinity optimization, and immunogenicity reduction.

Levitate competes with other providers of computational drug discovery software, such as Schrödinger and Dassault Systèmes BIOVIA, as well as specialized AI-driven biotech companies like Absci and Isomorphic Labs. Its unique differentiator is its exclusive focus on productizing and democratizing the Nobel-prize recognized Rosetta software, combined with its non-profit, foundation-owned mission aimed at tool accessibility rather than pure therapeutics development.